syngene: Syngene gets booster dose of sky-high valuation, but investors cautiously upbeat on stock

Contract research and manufacturing company Syngene International has had a fabulous run this year. Its stock price has risen over 40% since January amid robust growth and a positive outlook for the business. Syngene’s market capitalisation has reached INR33,000 crore, surpassing the INR32,600 crore market cap of its parent company Biocon. Since its listing in 2015, the Syngene stock has been rising steadily. Its market cap touched INR20,000

Leave a Reply

Your email address will not be published. Required fields are marked *